A Phase 2 interventional study of Nicotinamide in Chronic Kidney Disease, Hemodialysis and Hyperphosphatemia, sponsored by Medice Arzneimittel Pütter GmbH & Co KG. Completed at 36 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-18.
Sponsored by Medice Arzneimittel Pütter GmbH & Co KG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Renal Insufficiency, Chronic with a site in Germany — 26 open to participants now, 43 under way, 19 of them phase 3. Renal Insufficiency, Chronic · Germany.
Among the 232 studies in Renal Insufficiency, Chronic with a site in Germany, this one is the 72nd largest by enrollment of the 183 interventional ones that give a count, is one of 10 that started in 2010, is one of 40 in phase 2, and was the 53rd registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →26 of the 232 studies in Renal Insufficiency, Chronic with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Germany, United States, Argentina and 34 more countries
Ages 18+
Eli Lilly and Company · Sites in Germany, Argentina, Australia and 35 more countries
Ages 50+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Germany, United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 44 · Phase 3 80 · Phase 4 9
First in 2001; this study’s year is marked. 10 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 140 across the 183 interventional studies, 500 across the 49 observational. Of the 175 that completed or were terminated, 88 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 232 have an industry lead sponsor. The 10 most frequent:
Medice Arzneimittel Pütter GmbH & Co KG is the lead sponsor of 10 studies on the registry; none are open to participants now.
Medice Arzneimittel Pütter GmbH & Co KG has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
14 of the studies in Renal Insufficiency, Chronic with a site in Germany that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 14 to your calendar (.ics) → With an account.
Among the 232 studies in Renal Insufficiency, Chronic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study hypothesis: Nicotinamide inhibits gastrointestinal phosphate absorption and serum phosphate levels of dialysis patients in a dose dependent manner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nicotinamide
Drug: Nicotinamide
Drug: Nicotinamide
Drug: Nicotinamide
Drug: Nicotinamide
dosage
serum phosphate
Time frame: 4 weeks of active treatment
serum phosphate
Time frame: 8 weeks of active treatment
serum calcium
Time frame: 4 and 8 weeks of acitve treatment
serum PTH
Time frame: 4 and 8 weeks of active treatment
adverse events
Time frame: 12 weeks
The record gives a start of Aug 2010, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niacinamide
Renal Insufficiency, Chronic →
Medice Arzneimittel Pütter GmbH & Co KG